1.
Clin Case Rep
; 9(3): 1167-1170, 2021 Mar.
Article
in English
| MEDLINE | ID: covidwho-1009044
ABSTRACT
Autologous hematopoietic cell transplantation following induction therapy is standard of care for most patients with newly diagnosed multiple myeloma (N Engl J Med 2017, 376; 1311). Though active COVID-19 infection is typically a contraindication to aggressive therapy, little is known about the safety of autologous transplantation after resolution of acute symptoms and undetectable pathogen by nasopharyngeal PCR.